Biogen - BIIB Stock Forecast, Price & News

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Stock Up 1.6 %

BIIB Stock opened at $221.04 on Thursday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.68 and a current ratio of 1.94. The business's 50 day moving average price is $209.10 and its two-hundred day moving average price is $209.18. Biogen has a fifty-two week low of $187.16 and a fifty-two week high of $351.86. The company has a market capitalization of $32.08 billion, a price-to-earnings ratio of 15.77, a price-to-earnings-growth ratio of 1.00 and a beta of 0.40.

Biogen (NASDAQ:BIIB - Get Rating) last released its quarterly earnings results on Wednesday, July 20th. The biotechnology company reported $5.25 earnings per share for the quarter, beating the consensus estimate of $4.09 by $1.16. The firm had revenue of $2.59 billion for the quarter, compared to analysts' expectations of $2.48 billion. Biogen had a return on equity of 22.36% and a net margin of 19.36%. The company's revenue was down 6.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.68 EPS. As a group, analysts forecast that Biogen will post 16.36 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on BIIB. Oppenheimer increased their price target on shares of Biogen from $225.00 to $230.00 and gave the company an "outperform" rating in a report on Monday, July 18th. Robert W. Baird reiterated a "neutral" rating and set a $224.00 price objective on shares of Biogen in a research note on Tuesday, August 2nd. Truist Financial decreased their target price on shares of Biogen from $320.00 to $270.00 and set a "buy" rating for the company in a research report on Thursday, July 21st. SVB Leerink cut their price objective on shares of Biogen from $300.00 to $270.00 and set an "outperform" rating for the company in a report on Thursday, April 21st. Finally, StockNews.com raised shares of Biogen from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, July 27th. Thirteen equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $257.36.